From: Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
Drugs and indentifier | The role of China | Phase | Indication | Design | State | Enrollment |
---|---|---|---|---|---|---|
SHR-1210 CTR20160175 | Sponsor | I | Advanced solid tumors | Non-randomized, open-label, single-center, dose-escalation | Recruiting | 45 |
SHR-1210 CTR20170090 | Sponsor | II S + A | Advanced NSCLC | Non-randomized, open-label, single-center, dose-escalation | Recruiting | 118 |
SHR-1210 CTR20170299 | Sponsor | II | Advanced NSCLC | Open-label, single-arm, multicenter | Not yet recruiting | 120 |
SHR-1210 CTR20170322 | Sponsor | III S + P + C | Advanced non-squamous NSCLC | Randomized, open-label, multicenter | Not yet recruiting | 412 |
JS-001 CTR20160274 | Sponsor | I | Advanced solid tumors | Open-label, single-group assignment | Recruiting | 54 |
IBI308 CTR20160735 | Sponsor | I | Advanced malignant tumors | Non-randomized, open-label, single-group assignment | Recruiting | 104 |
BGB-A317 CTR20160872 | Sponsor | I | Advanced solid tumors | Non-randomized, open-label, single-group assignment | Not yet recruiting | 300 |